Don Frail

Most recently, Don was a Senior Vice President in R&D at Allergan where he led an organization responsible for research and preclinical functions, clinical pharmacology, and the scientific arm of business development. He was a member of the CEO’s Operational Leadership Team, the R&D leadership team, and co-chair of the governance body for all pre-POC clinical programs. He reshaped the research strategy and elevated more than 10 programs into development, primarily in ophthalmology, dermatology and aesthetics, and neuroscience. He also made major contributions to quickly rebuilding the R&D pipeline through completion of over 25 business development deals. Prior to joining Allergan, Don was Vice President of Emerging Scientific Innovations at AstraZeneca, Chief Scientific Officer of the Indications Discovery Unit at Pfizer, VP Biology, St Louis site, at Pfizer, and Vice President of Neuroscience Discovery at Pharmacia. Don has served on the Board of Directors for Stealth Newco, Pandion Therapeutics, and AGN Holdco. Don earned a Ph.D. in Biochemistry from McGill University in Montreal, Quebec and completed a post-doctoral fellowship in Pharmacology and Neuroscience at the Washington University School of Medicine in St. Louis, MO. He has published many peer reviewed articles and is author of the book Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs.